Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
NCT06493552
Recruiting
Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary objective of this study is to demonstrate additive therapeutic benefit for sEphB4-HSA. The secondary objectives are to determine whether the sEphB4-HSA containing regimen is safe and whether the oncological endpoints of importance in each cohort improve as a result of treatment with sEphB4-HSA containing regimen relative to a predefined thresh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2025
Locations: Sarcoma Oncology Center, Santa Monica, California
Conditions: Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma
Register for Updates
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
NCT06115499
Recruiting
This phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemcitabine for the treatment of patients with pancreatic cancer that has spread to other places in the body (metastatic) and a known genetic mutation in the BRCA1, BRCA2, or PALB2 gene.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +308 locations
Conditions: Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Squamous Cell Carcinoma, Stage IV Pancreatic Cancer AJCC v8
Register for Updates
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
NCT03609216
Recruiting
This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Fairbanks Memorial Hospital, Fairbanks, Alaska +413 locations
Conditions: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Register for Updates
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596
Recruiting
This is a global, multicenter, randomized, open-label study, with an adaptive design. The main objective of the study is to measure the efficacy and safety of BT8009 (zelenectide pevedotin) as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC). The study includes a dose selection phase followed by an adaptive design continuation. The study is comprised of 2 cohorts. Cohort 1 will include participants who have not received... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +169 locations
Conditions: Metastatic Urothelial Cancer
Register for Updates
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
NCT02305654
Recruiting
This is an international phase III trial, with a Bayesian design, incorporating two sequential randomisations. It efficiently examines a series of questions that routinely arise in the sequencing of treatment. The study design has evolved from lengthy international consultation that has enabled us to build consensus over which questions arise from current knowledge and practice. It will enable potential randomisation for the majority of patients with inguinal lymph node metastases and will provi... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Los Angeles County-USC Medical Center, Los Angeles, California +16 locations
Conditions: Squamous Cell Carcinoma of the Penis, Usual Type
Register for Updates
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
NCT05298423
Active Not Recruiting
Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: VA Long Beach Healthcare System ( Site 2831), Long Beach, California +159 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718
Active Not Recruiting
This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Highlands Oncology Group, Springdale, Arkansas +228 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT04711824
Recruiting
This study is a Phase I/II study evaluating the safety and effectiveness of focused radiation therapy (radiosurgery) together with olaparib, followed by immunotherapy, for patients with brain metastases from triple negative or BRCA-mutated breast cancers. This study will have a Phase I portion in which subjects will be enrolled based on 3+3 dose escalation rules. Three dose levels of olaparib will be studied. Cycle 1 of study treatment will consist of Olaparib given twice daily concurrently wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +6 locations
Conditions: Breast Cancer, Brain Metastases, Adult
Register for Updates
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients with Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
NCT05681039
Recruiting
To learn if treatment with tiragolumab and atezolizumab before and after standard of care surgery and chemoradiation (radiation therapy with or without cisplatin/carboplatin) can help to control OCSCC that is PD-L1 CPS positive.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Register for Updates
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
NCT03215719
Recruiting
This will be a phase II single-arm clinical trial. The purpose of this study is to determine the feasibility of deescalating chemoradiation treatment based on mid-treatment tumor response determined by rapid nodal shrinkage and clearance of circulating HPV plasma tumor DNA . The primary objective of this study is to evaluate progression-free survival at 2 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: New York University School of Medicine, New York, New York
Conditions: Oropharyngeal Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Register for Updates
Radiotherapy with Cisplatin Vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
NCT02128906
Recruiting
The goal of this clinical research study is to learn which chemotherapy combination may be more effective in treating locally advanced head and neck squamous cell carcinoma (HNSCC). The side effects of these combinations will also be studied. This study treatment consists of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy. For study chemotherapy, patients will be randomized between cisplatin or the combination of docetaxel and cetuximab. Subjects will be stratified depe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: UPMC Hillman Cancer Center - Radiation Oncology, Pittsburgh, Pennsylvania
Conditions: Squamous Cell Carcinoma
Register for Updates
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
NCT04486833
Recruiting
The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nanoparticles that encapsulate a DNA plasmid with the TUSC2 tumor suppressor gene and is the first systemic gene therapy for cancer. The study is comprised of a Phase 1 dose escalation portion and two Pha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Valkyrie Clinical Trials, Los Angeles, California +7 locations
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates